Treatment of intraocular retinoblastoma with vincristine and carboplatin

Journal of Clinical Oncology

Volumn 21, Issue 10, 2003, Pages 2019-2025

  Rodriguez Galindo, Carlos ^a   Wilson, Matthew W ^a   Haik, Barrett G ^a   Merchant, Thomas E ^a   Billups, Catherine A ^a   Shah, Nirali ^a   Cain, Alvida ^a   Langston, James ^a   Lipson, Mindy ^a   Kun, Larry E ^a   Pratt, Charles B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; INFANT; MALE; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RETINA TUMOR; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EYE ENUCLEATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RETINAL NEOPLASMS; RETINOBLASTOMA; TENNESSEE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0038011920     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.103     Document Type: Article

References (50)

1. Gurney JG, Severson RK, Davis S, et al: Incidence of cancer in children in the United States: Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 75:2186-2195, 1995
2. Ross G, Lipper EG, Abramson D, et al: The development of young children with retinoblastoma. Arch Pediatr Adolesc Med 155:80-83, 2001
3. Uusitalo MS, Van Quill KR, Scott IU, et al: Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 119:41-48, 2001
4. Khelfaoui F, Validire P, Auperin A, et al: Histopathologic risk factors in retinoblastoma: A retrospective study of 172 patients treated in a single institution. Cancer 77:1206-1213, 1996
5. Namouni F, Doz F, Tanguy ML, et al: High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 33:2368-2375, 1997
6. Dunkel IJ, Aledo A, Kernan NA, et al: Successful treatment of metastatic retinoblastoma. Cancer 89:2117-2121, 2000
7. Naumova A, Sapienza C: The genetics of retinoblastoma, revisited. Am J Hum Genet 54:264-273, 1994
8. Wong FL, Boice JD, Abramson DH, et al: Cancer incidence after retinoblastoma: Radiation dose and sarcoma risk. J Am Med Assoc 278:1262-1267, 1997
9. Eng G, Li FP, Abramson DH, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121-1128, 1993
10. Mohney BG, Robertson DM, Schomberg PJ, et al: Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol 126:269-277, 1998
11. Yue NC, Benson ML: The hourglass facial deformity as a consequence of orbital irradiation for bilateral retinoblastoma. Pediatr Radiol 26:421-423, 1996
12. Kaste SC, Chen G, Fontanesi J, et al: Orbital development in long-term survivors of retinoblastoma. J Clin Oncol 15:1183-1189, 1997
13. Abramson DH, Frank CM: Second nonocular tumors in survivors of bilateral retinoblastoma: A possible age effect on radiation-related risk. Ophthalmology 105:573-580, 1998
14. Wilson MW, Rodriguez-Galindo C, Haik BG, et al: Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 108:2106-2115, 2001
15. Madden T, Sunderland M, Santana VM, et al: The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther 51:701-707, 1992
16. Rodman JH, Maneval DC, Magill HL, et al: Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer. Pharmacotherapy 13:10-16, 1993
17. Simon, R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
18. Chaum E, Ellsworth RM, Abramson DH, et al: Cytogenetic analysis of retinoblastoma: Evidence for multifocal origin and in vivo gene amplification. Cytogenet Cell Genet 38:82-91, 1984
19. Peto R, Pike MC, Armitage P: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
20. Shields CL, Honavar SG, Meadows AT, et al: Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133:657-664, 2002
21. Greenwald MJ, Strauss LC: Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology 103:1989-1997, 1996
22. Levy C, Doz F, Quintana E, et al: Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: Preliminary results. Br J Ophthalmol 82:1154-1158, 1998
23. Friedman DL, Himelstein B, Shields CL, et al: Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18:12-17, 2000
24. Beck MN, Balmer A, Dessing C, et al: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18:2881-2887, 2000
25. Gallie BL, Budning A, DeBoer G, et al: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114:1321-1328, 1996
26. Kingston JE, Hungerford JL, Madreperla SA, et al: Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 114:1339-1343, 1996
27. Smith MA, Rubinstein L, Ungerleider RS: Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 23:86-98, 1994
28. Chan HS, Lu Y, Grogan TM, et al: Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res 57:2325-2330, 1997
29. Chan HS, DeBoer G, Thiessen JJ: Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 2:1499-1508, 1996
30. Murphree AL, Villabianca JG, Deegan WF III, et al: Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114:1348-1356, 1996
31. Lumbroso L, Doz F, Urbieta M, et al: Chemothermotherapy in the management of retinoblastoma. Ophthalmology 109:1130-1136, 2002
32. Wilson TW, Chan HS, Moselhy GM, et al: Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol 114:1390-1395, 1996
33. Murray TG, Cicciarelli N, O'Brien JM, et al: Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol 115:1286-1290, 1997
34. Scott IU, Murray TG, Feuer WJ, et al: External beam radiotherapy in retinoblastoma: Tumor control and comparison of 2 techniques. Arch Ophthalmol 117:766-770, 1999
35. Hungerford JL, Toma NM, Plowman PN, et al: External beam radiotherapy for retinoblastoma: I. Whole eye technique. Br J Ophthalmol 79:109-111, 1995
36. Toma NM, Hungerford JL, Plowman PN, et al: External beam radiotherapy for retinoblastoma: II. Lens sparing technique. Br J Ophthalmol 79:112-117, 1995
37. Shields CL, Shields JA, Needle M, et al: Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 104:2101-2111, 1997
38. Gündüz K, Shields CL, Shields JA, et al: The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 116:1613-1617, 1998
39. Gombos DS, Kelly A, Coen PG, et al: Retinoblastoma treated with primary chemotherapy alone: The significance of tumor size, location, and age. Br J Ophthalmol 86:80-83, 2002
40. Shields CL, Honavar SG, Shields JA, et al: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460-464, 2002
41. Mendelsohn ME, Abramson DH, Madden T, et al: Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116:1209-1212, 1998
42. Abramson DH, Frank CM, Chantada GL, et al: Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet 20:31-36, 1999
43. Hayden BH, Murray TG, Scott IU, et al: Subconjunctival carboplatin in retinoblastoma: Impact of tumor burden and dose schedule. Arch Ophthalmol 118:1549-1554, 2000
44. Abramson DH, Frank CM, Dunkel IJ: A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106:1947-1950, 1999
45. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al: Second primary tumors in hereditary retinoblastoma: A register-based study, 1945-1997-Is there an age effect on radiation-related risk. Ophthalmology 108:1109-1114, 2001
46. Merchant TE, Gould CJ, Hilton NE, et al: Ocular preservation after 36 Gy external beam radiation therapy for retinoblastoma. J Pediatr Hematol Oncol 24:246-249, 2002
47. Shields CL, Meadows AT, Shields JA, et al: Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 119:1269-1272, 2001
48. Nishimura S, Sato T, Ueda H, et al: Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 19:4182-4183, 2001
49. Pui C-H, Ribeiro RC, Hancock ML, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
50. Blanco JG, Dervieux T, Edick MJ, et al: Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 98:10338-10343, 2001